Summary
Several mechanistic and serotonin-related statements are not addressed in the provided LYRICA label excerpts; approved indications and core mechanism-of-action binding are partly supported, but the overall alignment cannot be confirmed for many safety/label-relevant assertions due to missing label sections covering those topics.
Category Scores
Accurate Statements
Clinically, Lyrica is used for neuropathic pain.
Supported by Indications (Section 1) including neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia and neuropathic pain associated with spinal cord injury.
Clinically, Lyrica is used for fibromyalgia.
Supported by Indications (Section 1): Management of fibromyalgia.
Clinically, Lyrica is used for certain types of seizures.
Supported by Indications (Section 1): Adjunctive therapy for partial-onset seizures in patients 1 month of age and older.
Lyrica works mainly by binding to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system.
Supported by Mechanism of Action (Section 12.1): binds with high affinity to the alpha2-delta site.
Unsupported Statements
Lyrica (pregabalin) is not considered a serotonin drug or a serotonergic medication.
Not supported or addressed in the provided label excerpts; no serotonin/serotonergic classification language is included in Sections 1–17 excerpts provided.
Lyrica does not primarily increase or target serotonin (5-HT).
Not addressed in the provided label excerpts.
Binding to the alpha-2-delta subunit of voltage-gated calcium channels reduces release of several neurotransmitters involved in pain signaling.
The provided Mechanism of Action excerpt states binding to alpha2-delta site but does not include this downstream neurotransmitter-release mechanism.
Lyrica is not classified or prescribed as a serotonergic agent.
Not addressed in the provided label excerpts.
Lyrica is not the kind of drug expected to cause serotonergic-toxicity syndromes on its own.
Serotonergic toxicity/expected syndromes are not addressed in the provided label excerpts.
Serotonergic drugs include SSRIs (e.g., sertraline, fluoxetine).
Not addressed in the provided label excerpts.
Serotonergic drugs include SNRIs (e.g., venlafaxine, duloxetine).
Not addressed in the provided label excerpts.
Serotonergic drugs include MAO inhibitors.
Not addressed in the provided label excerpts.
Serotonergic drugs include triptans (migraine).
Not addressed in the provided label excerpts.
Contradictions
Important Omissions
The AI statements do not cite or reflect key LYRICA label safety information that could be relevant to serotonin/toxicity claims (e.g., warnings/precautions such as suicidal ideation/behavior, respiratory depression, somnolence/dizziness) and contraindications/hypersensitivity. If the intended purpose was to justify safety, those label items are not included.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response does not provide dosing, contraindication, or direct treatment guidance. However, multiple serotonin-related assertions are not supported by the provided label excerpts, so the safety rationale relative to FDA labeling cannot be verified.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Many claims about serotonergic status and serotonin toxicity are not addressed in the provided label excerpts, and one downstream mechanism detail (neurotransmitter release reduction) is not explicitly supported by the supplied Mechanism of Action excerpt.
Suggested Improvement
Limit claims to label-supported content from the provided excerpts (e.g., approved indications in Section 1 and binding to alpha2-delta site in Section 12.1). Remove or rephrase serotonin/toxicity statements unless supported by specific FDA label text included in the provided materials.